Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Endocrinology year 2 > Neurohypophyseal disorders > Flashcards

Neurohypophyseal disorders Flashcards

1
Q

How does the posterior pituitary gland appear on the MRI

A

‘bright spot’ on pituitary MRI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Name the two main nuclei within which neurones of the neurohypophysis have their cell bodies.

A

Paraventricular Nucleus - BOTH MAGNOCELLULAR AND PARVOCELLULAR HORMONES
Supraoptic Nucleus- MAGNOCELLULAR HORMONES ONLY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which two hormones are produced by the neurohypophsyis

A

Vasopressin and Oxytocin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Revise year 1 endocrinology

A

§ Magnocellular neurones – neurones that project into the neurohypophysis (with herring bodies).
§ 2 neurohypophysis hormones:
o Oxytocin.
o Vasopressin (ADH) – reduces urine output.
§ Vasopressin acts by increasing water reabsorption from renal cortical and medullary collecting ducts via V2 receptors.
§ Anti-diuretic = against increase in urine production.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Summarise the principal effects of vasopressin

A

Principal effect of vasopressin = ANTI-DIURETIC ie increases water reabsorption from renal cortical and medullary collecting ducts via V2 receptors
Vasopressin also known as ADH – Anti Diuretic Hormone
Diuresis = increase in urine production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the posterior pituitary gland composed of

A

Comprised of nerve axons descending through the pituitary stalk from their cell bodies in the hypothalamus, and numerous glial cells called pituicytes which make up the bulk of the neural lobe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the distinguishing features of the magnocellular neurones

A

Larger than normal neurones (parvocellular neurones)
Unmyelinated fibres, have the distinguishing features of herring bodies (swellings) along the axon, particularly near the nerve terminals. The nerve terminals, and indeed many of the herring bodies are in close contact with the walls of a capillary network in the neural lobe. The capillaries are typically fenestrated, allowing the passage of molecules released from nerve endings, and probably from the herring bodies, into the general circulation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Where are the paraventricular and supraoptic nuclei found

A

PVN- close to the walls of the 3rd ventricle

SON- above the optic chiasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Where do the parvocellular neurones terminate

A

In the median eminence or to other parts of the brain. The neurosecretions from the parvocellular fibres terminating in the median eminence reach the cells of the anterior pituitary via the hypothalamo-adenohypophysial portal system. The main one being vasopressin as a corticotrophin-releasing factor for corticotrophs.

In the CNS- their neurosecretions act as neurotransmitters or neuromodulators
Also synthesise somatostatin, CRH and TRH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Why may it be possible for parvocellular neurones to have central effects

A

Increasing evidence that neurosecretions can be released at dendritic endings. Some parvocellular have dendritic endings abutting into the third ventricle- thus some hormones may be released into the CSF- particularly in parts of the brain devoid of vasopressinergic or oxytocinergic nerve endings but having abundant receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the principal action of vasopressin and how does it carry out this action?

A

Vasopressin’s main action is on the V2 receptors in the renal cortical and medullary collecting ducts
It stimulates the synthesis and assembly of aquaporin 2, which then increases water reabsorption and has an antidiuretic effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the V2 receptor and its signalling pathway

A

The V2 receptor is linked to a Gs receptor- and the enzyme activated is adenyl cyclase - converting ATP to cAMP which then activates PKA, which in turn phosphorylates other intracellular proteins including CREB.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How does vasopressin then illicit its effects

A

A key molecule influenced are the aquaporins. These are proteins which can be inserted into cell membranes where they act as pores through which water can pass, up an osmotic gradient.
The principal cells of the renal collecting ducts synthesise a vasopressin-dependent aquaporin (AQP2)
which is essential from the movement of water from the tubular fluid into the cells.
Vasopressin induces not only the synthesis of AQP2 but also its transport (within vesicles called aggraphores) to the apical membranes of the principal cells where they are inserted. Water moves out the principal cells via different aquaporins in the basolateral membranes (AQP3 and AQP4) and only AQP3 is vasopressin sensitive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Ultimately, what regulates vasopressin

A

Osmoreceptors- neurones which look at osmolality (how concentrated the solution is)
Not much change in osmolality on a daily basis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the osmoreceptors

A

The change is plasma osmolality is detected by osmosensitive (stretch-responsive) cells that are in contact with the general circulation but also able to communicate with the vasopressinergic in the hypothalamus. These osmoreceptors exist in certain structures called circumventricular organs, which are found in the anterior hypothalamus, close to the third ventircles, all of which importantly have fenestrated capillaries (i.e no BBB) and so are in contact with diffusible molecules, such as sodium ions in the blood.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Where are these osmoreceptors found primarily

A

the organum vasculosum of the lamina terminalis and the sub-fornical organs from where axons contact the vasopressinergic neurones in the PVN and SON directly or indirectly.
They may well also influence other parts of the CNS, where they exert effects such as influencing drinking behaviour.
it is also worth noting that there is evidence to suggest that the firing rate of vasopressinergic neurones is also increased directly when the osmolality of the surrounding medium is increases, indicating that these neurones may be osmosensitive themselves.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What happens to the osmoreceptors as plasma osmolality increases

A

When blood osmolarity goes up, water moves out of osmoreceptor cells and the osmoreceptors shrink which triggers them to send more signals to the hypothalamus to release VP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Describe the response seen in water deprivation

A

Increased blood plasma osmolarity - stimulation of osmoreceptors (thirst) - increased VP release - increased water reabsorption from renal collecting ducts - reduction in blood plasma osmolarity & reduced urine volume (but higher urine osmolarity).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What else can stimulate vasopressin release

A

Low blood volume and BP ( baroreceptors both high pressure- responding to high BP and low pressure- responding to volume (venous blood volume)- normally have an inhibitory effect on VPP release- so when they are not stimulates- lose inhibition- leading to VPP release

Stressors- pain and surgery- visceral information (food being eaten) is associated with increased VPP released before any food constituents have been absorbed, via vagal afferent projections to the brainstem and hence the hypothalamus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are the consequences of a lack of the neurohypophysial hormones?

A

Lack of Oxytocin – not clinically significant

Lack of Vasopressin – Diabetes Insipidus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Ultimately, what is diabetes insipidus

A

Absence or lack of circulating vasopressin (cranial or central)

End-organ (kidneys) resistance to vasopressin (nephrogenic)- rarer

Can’t reabsorb water properly from the collecting duct

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Outline the causes of cranial diabetes insipidus

A

Acquired (more common)
Damage to Neurohypophysial system
Traumatic brain injury
Pituitary surgery- posterior lobe removed or damaged
Pituitary tumours, craniopharyngioma- benign anterior lobe disease does not usually affect the posterior lobe
Metastasis to the pituitary gland eg breast
Granulomatous infiltration of median eminence eg TB, sarcoidosis- neurones must pass down stalk through median eminence to reach the posterior lobe- so any inflammation here or damage may affect the function of the posterior lobe
Congenital - rare

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Outline the causes of nephrogenic diabetes insipidus

A

Congenital - rare (e.g. mutation in gene encoding V2 receptor, aquaporin 2 type water channel)
Acquired - Drugs (e.g. lithium, dimethyl chlortetracycline (DMCT) )- used to treat schizophrenia (can also cause primary hypothyroidism).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Outline the signs and symptoms of diabetes insipidus

A

Large volumes of urine (polyuria)
Urine very dilute (hypo-osmolar)
Thirst and increased drinking (polydipsia)
Dehydration (and consequences) if fluid intake not maintained - can lead to DEATH
Possible disruption to sleep with associated problems- patients have to wake up repeatedly in the night to pass urine
Possible electrolyte imbalance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Ultimately, what are patients with diabetes insipidus unable to do

A

Increase urine osmolality in response to water deprivation test (as they can’t reabsorb water)- so urine osmolality stays low

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Describe the physiological response that occurs in patients with diabetes insipidus

A

INADEQUATE PRODUCTION OF/RESPONSE
TO VP

LARGE VOLUMES OF DILUTE (HYPOTONIC) URINE

INCREASE IN PLASMA OSMOLALITY (AND SODIUM)

REDUCTION IN EC FLUID VOLUME

THIRST - POLYDIPSIA

EC FLUID VOLUME
EXPANSION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What can happen to patients in diabetes insipidus if they don’t have access to enough water

A

Dehydration and death

Can’t reabsorb any water- so only way to reduce plasma osmolality and increase EC volume it by fluid intake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

State another cause of polydipsia that isn’t diabetes.

A

Psychogenic polydipsia

This is a central disturbance that increases the drive to drink

29
Q

Describe psychogenic polydipsia

A

Most frequently seen in psychiatric patients – aetiology unclear, may reflect anti-cholinergic effects of medication – ‘dry mouth’
Can be in patients told to ‘drink plenty’ by healthcare professionals
Excess fluid intake (polydipsia) and excess urine output (polyuria) – BUT unlike DI, ability to secrete vasopressin in response to osmotic stimuli is preserved

30
Q

Describe the physiological response seen in patients with psychogenic polydipsia

A

INCREASED DRINKING (POLYDIPSIA)

EXPANSION OF EC FLUID VOLUME,
REDUCTION IN PLASMA OSMOLALITY

LESS VP SECRETED BY POSTERIOR PITUITARY

LARGE VOLUMES OF DILUTE (HYPOTONIC) URINE

EC FLUID VOLUME RETURNS TO NORMAL

INCREASED DRINKING (POLYDIPSIA)

31
Q

Difference between psychogenic polydipsia and diabetes insipidus

A

DI people will have a HIGH plasma osmolarity and PP people will have a LOW osmolarity (even though they both drink a lot of water – difference lies in differences in VP)

32
Q

Quantify the plasma osmolality values seen in patients with diabetes insipidus and compare this to the norm and in patients with psychogenic diabetes polydipsia

A

Normal- 270-290 mOsm/kg H2O
Diabetes insipidus- >290mOsm/kgH20
Psychogenic polydipsia- <270 mOsm/kgH20

33
Q

What test can be used to distinguish between normal, psychogenic polydipsia, central DI and nephrogenic DI? Describe the results you would expect.

A

Fluid deprivation test
· Normals and psychogenic polydipsia will show a rise in urine osmolality
· Central and nephrogenic diabetes insipidus will show little or no change in urine osmolality
Fluid deprivation with administration of DDAVP (Desmopressin)
· Central diabetes insipidus will show a rise in urine osmolality
· Nephrogenic DI will still have a low urine osmolality (because of end-organ resistance)

34
Q

Summarise the water deprivation test

A

§ Each column is a osmolarity test under different conditions.
§ DDAVP is synthetic AVP – differentiates cranial and central.
§ A cannula is inserted to take regular readings.
§ Patients’ weight is taken regularly to make sure they don’t become too dehydrated.
§ PP is very similar to normal as it’s mostly psychogenic!
o PP is slightly lower because the polydipsia has ‘washed away’ the concentration gradient in the medulla slightly.

35
Q

What is classes as a low urine osmolarity

A

Less than 500 mOsm/khH2O

36
Q

Why do we need to monitor body weight in the water deprivation test

A

Losing more than 3kg of body weight- stop the test- marker of clinical dehydration which could result in death.

37
Q

State the biochemical features of diabetes insipidus

A

Hypernatraemia
Raised urea
Increased plasma osmolality
Dilute (hypo-osmolar) urine - ie low urine osmolality

38
Q

Outline the biochemical features of psychogenic polydipsia

A

Mild hyponatraemia – excess water intake
Low plasma osmolality
Dilute (hypo-osmolar) urine - ie low urine osmolality

39
Q

Which tissues express the V1 receptor

A 
Vascular smooth muscle
Non-vascular smooth muscle
Anterior pituitary
Liver 
Platelets
CNS
40
Q

Which tissues express the V2 receptor

A

Kidney

Endothelial cells

41
Q

Why is the urine osmolality of someone with psychogenic polydipsia lower (in the fluid deprivation test) than a normal subject?

A

Over time, the constant passage of large volumes of water through the kidneys will wash out the osmotic gradient that is necessary for AVP to exert its diuretic effect

42
Q

Describe the normal change in urine osmolality as plasma osmolality increases.

A

Normally, urine osmolality will increase as plasma osmolality increases (in a graph of urine osmolality against plasma osmolality it will show a sigmoid shape)
In DI, there is little change in urine osmolality as plasma osmolality increases

43
Q

Describe changes in plasma vasopressin following administration of hypertonic saline in a normal subject, psychogenic polydipsia, central DI and nephrogenic DI.

A

Hypertonic saline will increase the plasma osmolality and hence will increase the vasopressin secretion in patients that have the capacity to produce vasopressin (normal, psychogenic polydipsia and nephrogenic DI)
Patients with central DI can’t produce vasopressin at all so the hypertonic saline will show no change in plasma vasopressin

44
Q

What is the issue with various tissues expressing vasopressin receptors and how do we circumnavigate this in terms of treatment

A

§ Remember that ALL vasopressin receptors will be activated – we want to target just the V2 kidney receptors.
§ To treat cranial DI, we use selective VP receptor agonists:
o V1 – Terlipressin.
o V2 – Desmopressin (DDAVP)

45
Q

Summarise the use of DDAVP

A

Administration
Nasally
Orally
SC
Reduction in urine volume and concentration in cranial DI
CARE – to tell patient starting this NOT to continue drinking large amounts of fluid – risk of hyponatraemia (used to drinking large amounts of water- but now they can reabsorb it all- leading to hyponatraemia)

46
Q

Describe the issue with giving DDAVP nasally

A

Makes the drug seem less important- especially if the patient has sinusitis- and so can impact drug adherence
If the patient has had the pituitary gland removed- don’t give nasally as they will have an inflamed nose from the operation.

47
Q

Describe the treatment of nephrogenic diabetes insipidus

A

Thiazide Diuretics (e.g. bendroflumethiazide)
This inhibits the Na+/Cl- pump in the DCT leading to a diuretic effect
This leads to volume depletion resulting in a compensatory increase in Na+ reabsorption from the PCT (plus a small decrease in GFR).
This increases proximal water reabsorption so less water reaches the collecting duct
This ultimately leads to reduced urine volume

48
Q

Why can’t we use DDAVP to treat nephrogenic diabetes insipidus

A

This is the only drug we have (thiazides) and it’s not very effective but it is VERY hard to treat (as the problem lies in the kidneys, not in the hormone itself).

49
Q

What can V1 peptidergic agonists be used to treat

A

Have powerful vasconstrictive effects

Hence can be used to treat oesophageal varices and to reduce G.I bleeds

50
Q

Describe the DDAVP as a molecule

A

Had arginine in the VVP modified to give it a longer half life, so that patients do not need administration of the drug every 5 minutes, as they would with naïve vasopressin. By using a D-amino acid (rather than L-arginine as occurs in nature), the molecule is realtively resistant to the usual degradative pathways.

51
Q

What can happen post-operatively to patients who have had their pituitary gland removed

A

Following transphenoidal pituitary surgery, some patients have transient diabetes insipidus, and one or two doses may be used in the days following the surgery if the patient starts to become hypernatremic until the pituitary recovers

52
Q

Describe the different routes in which DDAVP can be administered

A

Patients usually take DDAVP intravenously twice daily, and by giving vast doses a tablet of DDAVP is just about viable.
Most of an oral dose of DDAVP is digested, but enough survives to be reabsorbed and therapeutically useful- the oral dose is over 10 times that of the intranasal dose
As a trial, 0.5-1.0mcg of DDAVP can be given subcutaneously or intravenously.- this dose and route are sometimes used immediately post-operatively.
Patients who have permanent diabetes insipidus are usually offered intranasal therapy at a dse of about 10mcg per nostril once or twice daily, titrated to urine output and plasma sodium level.
A tablet of 100mcg is also available, and patients need between one and three of these up to four times daily because most of the drug is still destroyed in the digestive system.

53
Q

Define SIADH

A 
ADH (anti-diuretic hormone) = vasopressin
By definition
	the plasma vasopressin concentration 
		is inappropriately high for 
			the existing plasma osmolality
54
Q

Describe the physiology of SIADH

A

Increased VPP
INCREASED H20 REABSORPTION FROM RENAL COLLECTING DUCTS
EXPANSION OF ECF VOLUME
This leads to hyponatraemia and ANP release fron right atrium
This caused natriuresis- leading to hyponatraemia and euvolemia

55
Q

What are the key signs of SIADH

A

raised urine osmolality, decreased urine volume (initially)

decreased p[Na+] (HYPONATRAEMIA) mainly due to increased water reabsorption

56
Q

What are the symptoms of SIADH

A

can be symptomless
however if p[Na+] <120 mM: generalised weakness, poor mental function, nausea
if p[Na+] <110 mM: CONFUSION leading to COMA and ultimately DEATH

57
Q

Outline the causes of SIADH

A

CNS
SAH, stroke, tumour, TBI

Pulmonary disease
Pneumonia, bronchiectasis

Malignancy
Lung (small cell)

Drug-related
Carbamazepine (used to treat epilepsy), SSRI (selective serotonin reuptake inhibitors- depression- fluoxytine

Idiopathic

Ultimately, head or lung pathology
So do Chest X-Ray and CT of the brain- to see cause

58
Q

Describe the biochemistry of SIADH

A

Increased urine osmolality

Decreased plasma sodium and osmolality- mainly due to increased sodium reabsorption

59
Q

State some other causes of SIADH

A 
Neurohypophysial malfunction (e.g. meningitis, cerebrovascular disease) 
Thoracic disease (e.g. pneumonia) 
Endocrine disease (e.g. Addison’s) 
Physiological – it can happen under normal circumstances where AVP is release is stimulated by non-osmotic stimuli (e.g. hypovolaemia, pain, surgery)
60
Q

Summarise the treatment for SIADH

A

Appropriate treatment (e.g. surgery for tumour)

To reduce immediate concern, i.e. hyponatraemia
1. Immediate: fluid restriction
2. Longer-term: use drugs which prevent vasopressin action in kidneys
e.g. induce nephrogenic DI ie reduce renal water reabsorption - demeclocyline
inhibit action of ADH - V2 receptor antagonists

61
Q

Briefly explain the treatments for SIADH

A

§ To reduce immediate concern (i.e. hyponatraemia):
o Immediate – fluid restriction – thus won’t have water to reabsorb in the nephron.
o Long-term – demeclocyline – induce nephrogenic DI – reduce renal water reabsorption.
§ These prevent VP action in the kidney

62
Q

What are vaptans

A

Non-peptide vasopressin receptor antagonists
Tolvaptan = V2 receptor antagonist
It is used to treat hyponatraemia associated with SIADH and may be useful in treating congestive heart failure

63
Q

Summarise vaptans

A

Non-competitive V2 receptor antagonists
Inhibit aquaporin2 synthesis and transport to collecting duct apical membrane, preventing renal water reabsorption
Aquaresis – solute-sparing renal excretion of water, contrast with diuretics (diuresis) which produce simultaneous electrolyte loss
Licensed in the UK for treatment of hyponatraemia associated with SIADH
Very expensive – limits their current use

64
Q

Why don’t we give diuretics to patients with SIADH

A

Will also excrete electrolytes (inluciding Na+)- Na+ is already low-and so diuretics will just exacerbate problems

65
Q

Describe transient-pituitary driven SIADH

A

Lasts about a week, starting around 10 days after pituitary surgery. A well-described, but difficult to explain, pattern of events is for a transient diabetes insipidus to develop immediately following pituitary surgery for anterior pituitary disease, this being managed with careful fluid balance. Approximately 10 days later, some patients have an episode of SIADH that lasts about a week, and should be managed with fluid restriction. Patients who are unware of this sometimes feel thirsty and drink too much, resulting in transient hyponatraemia. An adequate fluid restriction is always sufficient to control this, and as it is transient any other therapy it is likely to cause an increased morbidity,

66
Q

Why is the use of ADH antagonists contra-indicted in transient SIADH

A

Will result in diabetes insipidus as soon as the patient normalises, and will confound further diagnostic tests

67
Q

State some clinical uses of Desmopressin.

A

Treatment of diabetes insipidus
Treatment of nocturnal eneuresis
Haemophilia (need V2 stimulation)
NOTE: it is taken orally or nasally

68
Q

State some unwanted effects of Desmopressin

A

Nausea
Headaches
Abdominal pain
Fluid retention and hyponatraemia

Endocrinology year 2 (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions